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Abstract
Over the last decades, genetic factors for rheumatoid diseases like
the HLA haplotypes have been studied extensively. However,
during the past years of research, it has become more and more
evident that the influence of epigenetic processes on the develop-
ment of rheumatic diseases is probably as strong as the genetic
background of a patient. Epigenetic processes are heritable
changes in gene expression without alteration of the nucleotide
sequence. Such modifications include chromatin methylation and
post-translational modification of histones or other chromatin-
associated proteins. The latter comprise the addition of methyl,
acetyl, and phosphoryl groups or even larger moieties such as
binding of ubiquitin or small ubiquitin-like modifier. The combinatory
nature of these processes forms a complex network of epigenetic
modifications that regulate gene expression through activation or
silencing of genes. This review provides insight into the role of
epigenetic alterations in the pathogenesis of rheumatoid arthritis
and points out how a better understanding of such mechanisms
may lead to novel therapeutic strategies.
Introduction
Rheumatic disorders comprise a large number of different
disease entities that are all characterized by musculoskeletal
symptoms. Rheumatoid arthritis (RA) not only has a high
prevalence but also represents the prototype of an autoimmune
inflammatory joint disease that leads to progressive destruction
of articular structures, particularly cartilage and bone [1].
Therefore, the impact of epigenetic modifications in the
development of rheumatoid diseases will be exemplified by
discussing epigenetic changes in RA by focusing on RA
synovial fibroblasts (RASFs). Hyperplasia of the synovium with
increased cell density and infiltration of inflammatory cells is a
hallmark of RA. Although the initiating events are elusive, it has
been shown that the interaction of RASFs with invading
macrophages, lymphocytes, and the endothelium leads to the
development of a specific tissue response. Matrix
metalloproteinase (MMP)-producing synovial cells invade into
the cartilage and into the subchondral bone. The attachment of
synovial cells and particularly of synovial fibroblasts to the
cartilage matrix as well as the subsequent upregulation of MMP
expression are the results of complex regulatory mechanisms.
So far, several genetic factors predisposing for RA have been
described, and in particular the influence of distinct HLA
haplotypes on disease development and severity has been
studied intensively. In addition, polymorphisms of other genes
such as PTPN22 have been demonstrated to play a role in
the pathogenesis of RA. However, the overall contribution of
these genetic susceptibility factors to the development of RA
is estimated to be 50% or even less [2], and numerous
studies suggest that other nongenetic but nevertheless gene-
regulating factors might individually influence both the
susceptibility to RA and disease severity. In this context, a
variety of alternative mechanisms of gene regulation have
been studied with special focus on epigenetic mechanisms
since there is robust evidence that epigenetic modifications
are associated with various pathologies such as cancer or
chronic inflammation. Given the fact that the whole genome
consists of more than 3 billion base pairs, the relatively low
number of coding sequences is surprising. Differences,
therefore, are likely to be based to a considerable extent on
epigenetic changes.
Two typical epigenetic modifications with great influence on
DNA function are well known, DNA methylation and histone
modification. Furthermore, alternative splicing of mRNA
expands the mechanisms by which signaling pathways can
be influenced. Additionally, recently, a group of endogenous,
small, noncoding RNAs, called microRNAs (miRNAs), has
been discovered as a new class of regulators of gene func-
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tion [3-5]. Though not fixed in the DNA code, these changes
can be stable over the entire human life span or may be
influenced by other factors such as individual differences in
lifestyle [6,7]. Given this complex molecular networking,
epigenetic factors may be of key impact on the pathogenesis
of RA. This hypothesis is supported by the notion that, in
addition to genetic factors, environmental triggers are
involved in the development of RA since age, infections,
smoking, nutrition, and pollution have been suggested to
have an effect on the epigenetic background. Although it is
still unknown how these factors contribute to the
development of RA in different patients, it is intriguing to
speculate that, for instance, the late onset of RA can be
explained by the development of a specific epigenetic back-
ground during a lifetime as it has been shown in cancer for
false patterns of methylation [6,8]. By comparing mono-
cygotic twins, it has been demonstrated that very similar
epigenetic patterns in young twins drift apart over a lifetime,
affected by different lifestyles [9]. Most changes were found
in patterns of histone deacetylation and methylation. In
conclusion, knowledge of the epigenetic processes becomes
more and more essential for the understanding of the
differences seen in the clinical picture of patients with
rheumatic diseases such as RA.
Epigenetic modulation of gene expression
The process of gene induction comprises the recruitment of
activator or repressor proteins that influence DNA binding,
synchronization, and recruitment of RNA polymerase II (RNA-
Poly II) to a specific gene. Furthermore, the process requires
formation of a whole complex formed by cofactors that are
termed enhancosomes. Subsequently, a complex interplay of
histone modification and transcriptional activation leads to the
induction of specific genes. The term ‘epigenetic’ (first
mentioned by Conrad Waddington in 1942) defines all
heritable changes in the expression of genes which are not
encoded directly by the DNA sequence of the specific gene
itself [10]. This includes DNA methylation, post-transcriptional
modifications, chromatin modification, and miRNAs. Epi-
genetic modifications are a prominent mechanism by which
the differentiation of cells is controlled since some genes are
repressed by epigenetic silencing during cell development.
Epigenetic silencing does not depend on sequence-specific
DNA-binding proteins [11]. This feature of epigenetic gene
control is important because it may explain how alterations in
epigenetic gene regulation may result in tumor genesis or
chronic inflammation without clonal expansion of defective
cells. Though completely different, the distinct epigenetic
factors can interact with each other since there is no clear
border between these regulatory pathways. Thus, it is known
that a complex interplay between transcription and RNAi (RNA
interference) can influence the heterochromatin structure [12].
Modification of histones
The DNA is highly organized within the chromatin. This
protein-DNA complex compresses the DNA in the nucleus. It
can be subdivided into euchromatin and heterochromatin.
Euchromatin is decondensed and transcriptionally active
whereas heterochromatin is condensed and transcriptionally
silenced [13]. Despite the clear distinction of heterochromatin
and euchromatin, the chromatin is dynamically modified [14].
The nucleosomes of the protein-DNA complex consist of 4
core histones each surrounded by 146 nucleotides. A highly
compact state of chromatin reduces the accessibility of the
DNA for transcriptional factors or the RNA-Poly II. Thus, the
expression rate of these genes is reduced. The unwinding of
the compact chromatin opens the DNA for polymerases or
transcription factors and thus initiates transcription. The
acetylation of histones is catalyzed by the histone acetyl-
transferases (HATs), which modify lysine residues at the
N-terminus of the histones [15]. Such hyperacetylation is
associated with the opening of the chromatin and thus with
an enhanced rate of gene transcription. On the other hand,
targeted deacetylation of histones is performed by multi-
subunit enzyme complexes (for example, the histone
deacetylases [HDACs]) [15]. HDACs remove the acetyl
group from the histone lysine residues, and the resulting
hypoacetylation of the histones reduces the space between
the histones and the surrounding DNA. Consequently, the
transcription factors are sterically hindered from binding to
their motifs on the nucleotide sequence, leading to a
silencing of affected genes [14]. The delicate balance
between histone acetylation and deactetylation modulates
the transcription rates of numerous genes. In addition, both
HATs and HDACs have a wide range of protein substrates
other than histones. These substrates can modify the activity
of proteins involved in transcription, nuclear translocation,
and cytoskeletal architecture. Hyperacetylation as well as
hypoacetylation of genes have been shown to be associated
with disease states. So far, the beneficial therapeutic use of
HDAC inhibitors has been shown in cancer [16] but also in
animal models of autoimmune diseases such as multiple
sclerosis [17] and systemic lupus erythematodes [18]. In
systemic sclerosis (SSc), the knockdown of HDAC7 in skin
fibroblasts [19] and the treatment of bleomycin-induced skin
fibrosis in mice with trichostatin A as a known HDAC inhibitor
[20] remarkably reduced the accumulation of extracellular
matrix proteins and therefore fibrosis [21]. In contrast to
previous studies demonstrating the successful application of
an HDAC inhibitor in vitro [22] and in an animal model of RA,
a recently published report gave evidence of hyperacetylation
in RA by comparing nuclear extracts of RA synovial tissue
samples with osteoarthritis (OA) tissue samples. The authors
found the activity of HDACs to be about twofold lower in
extracts of RA patients than in those of OA patients [23].
Therefore, changes in the acetylation pattern in RA have to be
addressed in further studies before thinking of molecular
therapeutic targets. Besides acetylation, there is increasing
evidence that methylation [24] or demethylation and also
citrullination [25] of histones might extend the epigenetic
modifications even though their role in autoimmune disease
has not been intensively studied so far.Page 3 of 9
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DNA methylation
The only known mechanism for a direct modification of DNA
sequences after their synthesis is the methylation of
nucleotides. This modification changes the function of the
methylated DNA dramatically. In eukaryotes, methylation is
restricted to the pyrimidin base cytosine, whereas in pro-
karyotes adenosin can be methylated as well. In prokaryotes,
DNA methylation functions as a control mechanism for the
restriction system that protects the cells against foreign DNA
molecules. In eukaryotes, the silencing of specific genes
seems to be the main function of methylated cytosines. In its
most common form, DNA methylation takes place at position
5 of the cytosine ring within CpG dinucleotides [26].
Nonmethylated CpG dinucleotides are clustered in regions
called CpG islands. Generally, these CpG islands surround
the promoter region of constitutive exprimated genes. There
are several DNA methyltransferases (Dnmts) that can
catalyze these methylation processes, Dnmt 1 as the most
abundant methyltransferase. The Dnmt3 family which is
capable to methyltes hemi- or unmethylated CpGs. Insertion
of a methyl group into DNA by Dnmts results in changes of
chromatin formation and in silencing of the affected gene.
There are two functional principles of methylation-mediated
DNA silencing that can be distinguished. First, direct binding
of a transcription factor is hindered, which is caused by
sterical changes of the sequence structure. Second, the
recognition of a methylated nucleotide can elicit the
repressive potential of these regions. Methyl CpG-binding
proteins use transcriptional corepressors for transcriptional
silencing or may modify the surrounding chromatin of
methylated regions [27]. In oncogenesis, hypermethylation of
tumor-suppressor genes and hypomethylation of proto-
oncogenes are well-known epigenetic phenomena. The
aggressive and invasive behavior of RASFs and their
increased resistance to apoptosis explain why they are also
referred to as cells with a ‘tumor-like phenotype’ [28]. While
there is no genetic background for these alterations, it
becomes more and more obvious that epigenetic
modifications trigger or at least contribute to the
characteristic changes of RASFs. Methylation of CpG islands
in the promoter region of the Death receptor 3 (DR3) of
RASFs results in a higher resistance for apoptosis [29].
Another study supported the findings of an altered resistance
to apoptosis due to epigenetic modifications by showing that
treatment with the HDAC inhibitor trichostatin A induces
apoptosis in RASFs, while concomitantly FLIP (Flice inhibitory
protein) was found to be silenced [30]. Inherited retroviral
sequences like LINE-1 (long interspersed nuclear element-1)
retrotransposons are known to play a role in cancer.
Strikingly, Neidhart and colleagues [31] showed an increased
expression in RA synovium, especially at sites of invasion.
Although most of the retrotransposons of the human genome
were not functional any more or were silenced by methylation,
RASFs showed an increased activity, probably due to a
decreased methylation of their promoter [32]. Enforced
expression of LINE-1 sequences in RASFs induced the
expression of the p38δ mitogen-activated protein kinase, the
c-Met receptor, and galectin 3-binding protein, thus
contributing to the activated phenotype of RASFs. The
increased activity of LINE-1 was associated with genomic
hypomethylation in RASFs. In accordance, very recent data
strongly support the hypothesis that genomic
hypomethylation might play a key role in the pathogenesis of
the activated phenotype of RASFs, in particular with respect
to their destructive potential. Karouzakis and colleagues [33]
were able to show the presence of hypomethylated nuclei in
the synovial tissue of RA patients, and additionally it has been
proven that RASFs retained their demethylation profile in
vitro. In further experiments, it had been demonstrated that
chronic treatment of normal synovial fibroblasts with the Dnmt
inhibitor 5-AZA (5-aza-2′-deoxycytidine) changed the cellular
profile into an RASF-like phenotype [33].
Besides RA, there is increasing evidence that histone
modifications of certain genes might play a role in the
pathogenesis of SSc. Recently, Wang and colleagues [34]
proved that hypermethylation of CpG islands and
deacetylation in the FLI-1 promoter region in SSc fibroblasts
and skin biopsy specimens were associated with increased
production of collagen type I. The direct influence of Dnmt3a
on the degree of histone modification has been shown [35].
A reduced Dnmt3a expression resulted in an enhaced
histone actylation. Tihis underlines the repressory nature of
Dnmt3a on acetylation of the core histones. Such findings
underline the complex interplay between the different factors
of the epigenetic network (Figure 1).
MicroRNAs
In the field of gene expression, a new class of post-trans-
criptional regulators has recently emerged. These small (19
to 22 nucleotides), endogenous, single-stranded, noncoding
RNAs, called miRNAs, account for 2% to 3% of the human
genome and are estimated to regulate about 30% of the
human genes [36]. Over 50% of known miRNAs are located
within introns of coding genes. The biogenesis of these
evolutionary highly conserved molecules is carried out in a
multistep process. Briefly, the mature single-stranded RNAs
are generated from genome-encoded stem-loop precursors.
This complex process is mainly catalyzed by two main RNAse
III-type endonucleases of which Drosha acts in the nucleus
whereas Dicer acts in the cytoplasm. Mature miRNAs that are
incorporated into the RNA-induced silencing complex (RISC)
recognize the 3′-untranslated region (3′-UTR) of their respec-
tive target mRNA by complementary base pairing with the
seed sequence (6 to 8 nucleotides) in their 5′-UTR. Based on
the fact that a complementarity of 6 nucleotides is sufficient
to exert regulatory functions, a single miRNA can potentially
interact with several hundred target mRNAs, and each mRNA
can be targeted by several miRNAs. This broad diversity of
possible interactions amplifies the complexity of the regula-
tion of protein-coding genes. The degree of complementary
of the seed sequence with the target mRNA determines the
Available online http://arthritis-research.com/content/10/5/219type of mechanism of this post-transcriptional regulation.
Perfect complementary is more common in plants than in
mammals and results in mRNA degradation [37]. In
mammals, the imperfect base pairing occurs more often, and
the miRNA-containing RISCs are thought to exert their
effects by regulating the stability of the target mRNA or by
blocking its translation [38]. Interestingly, there is increasing
evidence that miRNAs are not the only negative regulators of
gene expression. It has been found that, in response to
certain stimuli, sequestered mRNAs may be liberated and
even preferentially translated [39-40]. Given the complexity of
the mechanisms regulating gene expression, it seems likely
that miRNAs display additional functions aside from mere
switch-on or switch-off effects; for example, they might also
have ‘fine-tuning’ properties [31]. Besides this canonical
pathway, intronic miRNA precursors that bypass Drosha
processing have been discovered, first in Drosophila
melanogaster and Caenorhabditis elegans [41] and later in
mammals [42]. These so-called ‘mirtrons’ enter the pathway
of miRNA biogenesis after having been spliced and
debranched (Figure 2).
miRNAs have been found to be involved in physiological as
well as pathological processes, including cellular differen-
tiation, cell cycle progression and apoptosis, embryogenesis
[43], angiogenesis [44], (cardio-)myogenesis [45-47], meta-
bolism [48-50], neurology [43], oncogenesis, and viral infec-
tions [51]. In addition, there are rapidly accumulating data
implicating an important role of miRNAs in the regulation of
immune responses and the development of autoimmunity
[52-55]. Some recent studies have suggested that altered
expression and function of miRNAs might also be involved
into the pathogenesis of RA. Stanczyk and colleagues [56]
were able to show that the treatment of RASFs with tumor
necrosis factor-alpha (TNF-α) led to an upregulation of miR-
155 and miR-146 and that these two miRNAs were
constitutively more highly expressed in RASFs than in
synovial fibroblasts of patients with OA. Monocytes in the
peripheral blood of RA patients also displayed higher levels
of miR-155. Besides TNF-α, stimulation of RASFs with
interleukin (IL)-1β, lipopolysaccharide, poly(I-C), and bacterial
lipoprotein upregulated the expression of miR-155. Further-
more, the enforced expression of miR-155 repressed the
levels of MMP-3 and reduced the induction of MMP-3 and
MMP-1 by Toll-like receptor ligands and cytokines. Thus, it
could be hypothesized that, based on the repressive effect of
miR-155 on MMPs, miR-155 might play a role in the
modulation of the destructive behavior of RASFs [56]. These
findings were supported by another study that reported an
enhanced expression of miR-146 in RA synovial tissue and
demonstrated that the expression levels of miR-146 in RASFs
were increased upon stimulation with TNF-α and IL-1β [57].
The investigation of the impact of altered miRNA expression
is currently most advanced in cancer research. There is an
increasing number of studies providing new and profound
insights in the regulation of gene expression, in particular with
respect to the interference of former known epigenetic
modifications and miRNAs. Overexpression of certain
miRNAs such as miR-10b in breast cancer [58] and down-
regulation of miRNAs such as let-7 in non-small lung cancer
cells [59] or of miR-15 and miR-16 in chronic lymphocytic
leukemia [60] have been found to be implicated in tumor-
genesis. Most strikingly, there is increasing evidence that
miRNA-encoding genes are both regulators and targets of
methylation and acetylation processes. One recently
published study was able to show that, in non-small lung
cancer cells, the restoration of the downregulated miR-29
family reversed the altered methylation pattern and thus
induced re-expression of silenced tumor-suppressor genes
[61] because the members of the miR-29 family were proven
to be direct regulators of Dnmt3A and Dnmt3B. Another
cartilage-specific miRNA, miR-140, has been proposed to
target HDAC4 [61]. Besides, there are accumulating data
that miRNAs are also targets of the aforementioned
epigenetic modifications. In a large-scale analysis of human
miRNA genes, 155 of 332 miRNAs were found to be
associated with CpG islands, and the methylation frequency
was an order of magnitude higher than that of protein-coding
genes (1% to 2%) [62]. A recently published study showed
that treatment with chromatin-remodeling drugs, namely the
Arthritis Research & Therapy    Vol 10 No 5 Strietholt et al.
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Figure 1
Close interactions between DNA methylation and histone
modifications. (a) Relaxed chromatin is accessible for transcription
factors (TFs). Chemical modifications (green) on the core histones
(yellow) result in a relaxed chromatin structure. (b) DNA
methyltransferases (Dnmts) add methyl groups (grey triangle) to CpG
dinucleotides, resulting in gene silencing that can affect the former
modification of the histones. (c) The chemical modification (red) to the
core histone results in a condensed and inactive chromatin structure.
TFs are sterically hindered and cannot bind to their recognition
sequence on the DNA.demethylating agent 5-AZA and the HDAC inhibitor
phenylbutyrate (PBA), induced the expression of miR-127 in
cancer cells but not in normal fibroblasts. Alterations in DNA
methylation and histone modification around the promoter
region of the mir-127 gene by 5-AZA and PBA treatment
restored miR-127 expression in cancer cells with subsequent
suppression of the proto-oncogene BCL6 [63]. Given the
striking impact of altered miRNA expression on health or
disease, they represent promising future therapeutic targets.
That this aim is not beyond the realm of possibility is
supported by the successful and well-tolerated use of anti-
miRs in rodents [48,64] as well as in non-human primates
[65]. Besides systemic administration, a recently published
study has demonstrated that local delivery (that is,
intradermal application) of anti-miRs might be an alternative
strategy [66]. Based on these encouraging results, the first
human trial investigating the effects of anti-miR-122 in
patients with hepatitis C has now been initiated [67]. So far,
no adverse events have been reported. In contrast to the use
of anti-miRs, the induction of miRNA mimics in human trials
still has additional technical hurdles to face.
The discovery of miRNAs will also influence the design of
future experimental studies. Osokine and colleagues [68]
draw attention to the fact that, since the majority of the known
miRNAs are located within introns, unintentional ablation of
miRNA expression might be a major risk factor in gene
knockout studies. Their search of published murine knockout
studies and databases of gene trap embryonic stem cell lines
revealed almost 200 cases in which the knockout of the gene
might have disrupted miRNA expression. Based on the
demonstrated impact of an altered miRNA expression, it is
possible that the reported overt phenotypes might have been
more than the mere effect of the gene knockout [68].
Post-translational processes modulating
epigenetic mechanisms
There are different post-translational processes with direct or
indirect effect on epigenetic events. To illustrate this complex
mechanism, we will focus on two important factors, namely
ubiquitin and a related family of proteins, the small ubiquitin-
like modifiers (SUMOs). The latter proteins have been shown
to have a great influence on the ability of RASFs to react on
Fas-induced apoptosis. The well-described abilities of SUMO
and ubiquitin point out how important the interactions
between post-translational processes and epigenetics are.
Ubiquitin is an 8-kDa protein consisting of 76 amino acids.
Ubiquitination is a well-characterized process that labels
target proteins for proteasomal degradation. Additionally,
Available online http://arthritis-research.com/content/10/5/219
Page 5 of 9
(page number not for citation purposes)
Figure 2
MicroRNA (miRNA) biogenesis. The canonical pathway includes cleavage of pri-miRNAs in the nucleus by Drosha, whereas pre-miRNAs are
processed by Dicer in the cytoplasm. Some of the miRNAs located within introns of protein-coding genes bypass Drosha cleavage. These
so-called mirtrons are processed from their primary transcripts within an alternative (mirtronic) pathway by splicing and debranching. Finally, from
the resulting miRNA duplex, the strand with the higher affinity is assembled into the RNA-induced silencing complex. Complementary base pairing
with the target mRNA leads either to degradation of the mRNA or to translational repression, depending on the complement of the sequences. This
figure has been modified according to [40]. Ago, Agonaute proteins.ubiquitination controls the stability, function, and intracellular
localization of a wide variety of proteins. The multistep
process of ubiquitination is catalyzed by special enzymes and
can be completely reversed by deubiquitylating enzymes.
With respect to epigenetic modifications, it has been shown
that ubiquitination might interact with processes of
acetylation and methylation [69]. Additionally, it is well known
that at least three steps of the nuclear factor-kappa-B
(NF-κB) pathway are regulated by ubiquitination, namely
degradation of IkappaB (inhibitor of NF-κB), processing of
NF-κB precursors, and activation of the IkappaB kinase [70].
Taken together, these findings suggest that ubiquitination
might also play a significant role in the pathogenesis of RA
and that its further investigation with respect to this central
pathway might be promising.
Like ubiquitination, SUMOylation is an enzyme-catalyzed
multistep process that specifically targets proteins harboring
a SUMO interaction motif [71]. This process is also reversible
since the moieties of SUMO can be disconjugated from their
targets by specific proteases. With respect to epigenetic
regulation of gene expression, some published studies
suggest that SUMO promotes HDAC-mediated trans-
criptional repression [72,73]. SUMO-mediated transcriptional
repression might also involve certain transcription factors or
key molecules of signaling cascades. Besides, SUMO
modifies the activity and/or localization of proteins with
important roles in cell proliferation, differentiation, and
apoptosis [74]. However, the underlying molecular effects are
not well known yet.
In RA, there is evidence that SUMO is overexpressed in
synovial tissue and synovial fibroblasts [75]. Very recent data
showed that de-SUMOylation in RASFs decreased the levels
of histone acetylation with a subsequent reduction of the
expression of certain MMPs and ILs, thus diminishing the
destructive potential of RASFs [76]. Despite the fact that
chemical modulators of ubiquitination and SUMOylation are
already available, we first need a better understanding of the
underlying molecular mechanisms as well as of the epigenetic
impact of these modifications.
Epigenetic modifications regulating
inflammatory processes
The transcription factor NF-κB plays a central role in the
induction of genes involved in immunity and inflammation,
including cytokines, chemokines, adhesion molecules,
receptors, and inducible enzymes such as COX-2 and
inducible nitric oxide synthase [77]. Thus, the idea that the
inhibition of NF-κB could abrogate the signaling of pro-
inflammatory cytokines makes it an attractive therapeutic
target in RA. Interestingly, there is evidence that the binding
of NF-κB to its nucleosomal targets requires conformational
changes of histones to render its binding sites accessible
[78]. It has been shown that pro-inflammatory signaling
initiated modifications of histones such as acetylation of
histone 3, phosphoacetylation of histone 4, and reduced
methylation of H3K9 that was accompanied by activation of
RNA-Poly II. As a consequence of these modifications, an
increased recruitment of NF-κB to the promoter of several
cytokines and chemokines could be observed [79]. To add to
this complexity, IL-6, a major cytokine in the pathogenesis of
RA, is known not only to be an NF-κB-inducible gene but also
to initiate epigenetic modifications itself. In cancer, it has
been found that IL-6 enhanced and maintained the hyper-
methylation of the promoters of the tumor-suppressor gene
p53 and of hHR23B, a key factor of DNA repair in a multiple
myeloma cell line [80]. Furthermore, it has been demon-
strated to induce hypomethylation of the EGFR (epidermal
growth factor receptor) promoter, thus enhancing the
proliferation of cholangiocellular carcinoma cells [81].
Interestingly, there are accumulating data that enforced
expression of IL-6 in tumors alters not only the expression
levels of certain miRNAs [82,83] but also their methylation-
dependent regulation [84]. In summary, these findings
support the hypothesis that a highly complex epigenetic
control mediates immune and inflammatory responses.
Conclusion
The increasing amount of experimental in vitro and in vivo data
strongly supports the hypothesis that epigenetic modifications
play a major role in the development not only of cancer but
also of rheumatic diseases. In our review, we have focused on
RA not only to demonstrate that there are substantial
epigenetic modifications but also to illustrate their functional
impact. DNA methylation, histone modification, miRNAs, and
post-translational processes such as SUMOylation  directly
influence genes involved in inflammation and/or tissue
destruction. International projects and organizations such as
the Human Epigenome Project, the Epigenome Network of
Excellence, and the Epigenome Society reflect the
developing interest in this field. The main aims of the Human
Epigenome Project are the identification and cataloguing of
so-called methylation variable positions in the human genome.
The Epigenome Network of Excellence is a consortium of
European research trying to establish a European Research
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This article is part of a special collection of reviews, The
Scientific Basis of Rheumatology: A Decade of
Progress, published to mark Arthritis Research &
Therapy’s 10th anniversary.
Other articles in this series can be found at: 
http://arthritis-research.com/sbr
The Scientific Basis 
of Rheumatology: 
A Decade of ProgressArea with a clear focus on the epigenome, whereas the
Epigentic Society (formerly the DNA Methylation Society)
supports and enhances the networks between scientists with
a focus on epigenetic processes. Current and future research
will provide new insights into the complex pathogenesis of
rheumatic diseases and thus enable the development of a
molecular-based targeted therapy. That this is not beyond the
realm of possibility is supported by the fact that miRNA-
modulating agents have already entered clinical trials.
However, the application of epigenetic drugs other than
miRNA-targeting drugs in non-malignant diseases still has to
overcome major hurdles because of potential severe off-
target effects.
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